APPENDIX A: PENDING CLAIMS FOLLOWING ENTRY OF THE AMENDMENT

1. A method for treating a human subject having or suspected of having cancer or pre-cancerous disease comprising the steps of:

(i) identifying a subject having or suspected of having cancer or pre-cancerous disease characterized by alteration or increased expression of a self gene product in at least some of the cancer or pre-cancerous cells in said subject; and

(ii) intradermally administering to said subject an expression construct in an adenovirus particle comprising a self gene under the control of a promoter operable in eukaryotic dendritic cells, wherein the dendritic cells are infected by said construct,

whereby said self gene product is expressed by dendritic cells and presented to immune effector cells, thereby stimulating an anti-self gene product response.

2. The method of claim 1, wherein said self-gene product is an oncogene.

3. The method of claim 2, wherein said oncogene is selected from the group consisting of tumor suppressors, tumor associated genes, growth factors, growth-factor receptors, signal transducers, hormones, cell cycle regulators, nuclear factors, transcription factors and apoptic factors.

4. The method of claim 3, wherein said tumor suppressor is selected from the group consisting of Rb, p53, p16, p19, p21, p73, DCC, APC, NF-1, NF-2, PTEN, FHIT, C-CAM, E-cadherin, MEN-I, MEN-II, ZAC1, VHL, FCC, MCC , PMS1, PMS2, MLH-1, MSH-2, DPC4, BRCA1, BRCA2 and WT-1.

11. The method of claim 4, wherein said tumor suppressor product is p53.

15. The method of claim 1, wherein said adenovirus particle is replication-defective.

16. The method of claim 15, wherein the replication defect is a deletion in the E1 region of the virus.

17. The method of claim 16, wherein the deletion maps to the E1B region of the virus.

18. The method of claim 17, wherein the deletion encompasses the entire E1B region of the virus.

19. The method of claim 18, wherein the deletion encompasses the entire E1 region of the virus.

20. The method of claim 1, wherein said promoter is selected from the group consisting of CMV IE, human or murine dectin-1, human or murine dectin-2, human CD11c, mammalian F4/80 and human or murine MHC class II.

21. The method of claim 20, wherein said promoter is CMV IE.

22. The method of claim 1, wherein said expression vector further comprises a polyadenylation signal.

24. The method of claim 1, wherein said cancer is selected from the group consisting of lung, head, neck, breast, pancreatic, prostate, renal, bone, testicular, cervical, gastrointestinal, lymphoma, brain, colon, skin and bladder.

26. The method of claim 1, wherein said expression construct is administered via injection.

27. The method of claim 26, further comprising multiple injections.

28. The method of claim 26, wherein the injection is performed local to a cancer, a pre-cancer or a tumor site.

29. The method of claim 26, wherein the injection is performed regional to a cancer, a pre-cancer or a tumor site.

30. The method of claim 26, wherein the injection is performed distal to a cancer, a pre-cancer or a tumor site.

31. The method of claim 1, wherein intradermal administration is via continuous infusion.

33. The method of claim 1, wherein said immune effector cells are CTLs.

34. The method of claim 1, further comprising administering to said subject at least a first cytokine.

35. The method of claim 34, further comprising administering to said subject a second cytokine, different from said first cytokine.

36. The method of claim 34, wherein said cytokine is selected from the group consisting of GM-CSF, IL-4, C-KIT, Steel factor, TGF-β, TNF-α and FLT3 ligand.

37. The method of claim 34, wherein said cytokine is administered as a gene encoded by said expression construct.